Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Subscribe To Our Newsletter & Stay Updated
